Monoclonal antibody against nerve growth factor, and encoding gene and use thereof

Abstract

The present invention discloses a monoclonal antibody against nerve growth factor, and an encoding gene and use thereof. The monoclonal antibody comprises heavy chains comprising a heavy chain constant region and a heavy chain variable region, and light chains comprising a light chain constant region and a light chain variable region. The heavy chain variable region comprises three complementarity determining regions HCDR1, HCDR2 and HCDR3, and the light chain variable region comprises three complementarity determining regions LCDR1, LCDR2 and LCDR3. The monoclonal antibody can specifically bind to nerve growth factor, and can be used to detect the presence and/or level of nerve growth factor, as well as to prepare a drug for inhibiting the nerve growth factor-dependent proliferation of TF-1 cells, and for treating or preventing at least one of neuropathic pain, chronic pain, and inflammatory pain, thus having good application prospects and marketing value.

1 .- 15 . (canceled) 
     
     
         16 . A monoclonal antibody, or an antigen binding fragment thereof, comprising:
 a) a heavy chain variable region (V H ) comprising complementary determining regions (CDRs) having the amino acid sequences set forth in SEQ ID NOs: 5-7; and   b) a light chain variable region (V L ) comprising CDRs having the amino acid sequences set forth in SEQ ID NOs: 8-10.   
     
     
         17 . A method of using a pharmaceutical composition for inhibiting the proliferation of NGF-dependent TF-1 cells, wherein the pharmaceutical composition comprises a monoclonal antibody, or an antigen binding fragment thereof, comprising:
 a) a heavy chain variable region (V H ) comprising complementary determining regions (CDRs) having the amino acid sequences set forth in SEQ ID NOs: 5-7; and   b) a light chain variable region (V L ) comprising CDRs having the amino acid sequences set forth in SEQ ID NOs: 8-10.   
     
     
         18 . A method of preventing pain in a subject in need thereof, comprising administering to the subject at least one effective amount of a monoclonal antibody, or an antigen binding fragment thereof, comprising:
 a) a heavy chain variable region (V H ) comprising complementary determining regions (CDRs) having the amino acid sequences set forth in SEQ ID NOs: 5-7; and   b) a light chain variable region (V L ) comprising CDRs having the amino acid sequences set forth in SEQ ID NOs: 8-10.   
     
     
         19 . The method of  claim 18 , wherein the pain is neuropathic pain. 
     
     
         20 . The method of  claim 18 , wherein the pain is chronic pain. 
     
     
         21 . The method of  claim 18 , wherein the pain is inflammatory pain. 
     
     
         22 . The method of  claim 18 , wherein the pain is cancer pain.